March 14th 2023
Nurse researchers sought to improve the communication between the hematopoietic stem cell transplantation care team and pediatric patient caregivers.
Oncology Nurses Need Better Resources to Help Patients With Mental Health ProblemsOctober 4th 2022
Although oncology nurses are trained to show empathy and offer support, they lack the resources to adequately care for patients with acute mental health problems.
FDA Grants Ibrutinib Approval for Pediatric Graft-Versus-Host-DiseaseAugust 26th 2022
Ibrutinib is now an FDA-approved treatment for patients aged 1 year or older who have chronic graft-versus-host-disease. Prescription warnings include bleeding and cardiac problems, infections, high blood pressure, a decrease in blood cell count, and tumor lysis syndrome.
Collaboration Between Pediatric Oncology Nurses and Social Workers Decreases Treatment-Related DistressJuly 20th 2022
Pediatric oncology nurses and social workers routinely collaborate not only in the biopsychosocial assessment of families’ psychosocial needs and distress, but in developing interventions that can improve a patient’s and family’s quality of life while in pediatric cancer treatment and in survivorship.
Luspatercept Linked With Maintained Reduction in Transfusion Dependence Among Patients With β-ThalassemiaJune 24th 2022
Updated data from the phase 3 BELIEVE trial revealed a sustained reduction in the need for red blood cell transfusions among patients with β-thalassemia who received treatment with luspatercept-aamt.
Pediatric/Young Adult Patients With B-ALL Continue to Derive Benefit From Tisagenlecluecel at 5-Year Follow-UpJune 22nd 2022
Heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia maintained response with tisagenlecelucel according to long-term follow-up data from the phase 2 ELIANA trial.
FDA Approves Radiopharmaceutical Diagnostic Agent for Pediatric PatientsJune 10th 2021
The FDA approved injectable technetium Tc 99m tilmanocept (Lymphoseek), a radiopharmaceutical agent that targets lymphatic mapping and guiding for sentinel lymph node biopsies (SLNB), for use in pediatric patients with melanoma, rhabdomyosarcoma, and other solid tumors.
FDA Approves Crizotinib for Pediatric/Young Adult ALK+ Anaplastic Large Cell LymphomaJanuary 15th 2021
The FDA has approved crizotinib (Xalkori) for the treatment of pediatric patients 1 year of age and older and young adults with ALK-positive relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL).
Genetic Precursors to Pediatric Rhabdomyosarcoma IdentifiedJanuary 7th 2021
“But our study is pointing to new genes to consider. For example, we found that the BRCA2 gene, typically associated with adult breast and ovarian cancer, may also somehow influence the susceptibility of pediatric RMS.”
FDA Approves Pralsetinib for RET-Altered Thyroid CancersDecember 2nd 2020
The FDA approved pralsetinib (Gavreto) for adults and children aged 12 or older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who need systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory.
FDA Approves Naxitamab-gqgk for Pediatric and Adult High-Risk NeuroblastomaNovember 26th 2020
The FDA has granted an accelerated approval to naxitamab-gqgk (Danyelza) for use in combination with granulocyte-macrophage colony-stimulating factor as a treatment for pediatric patients 1 year of age and older and adult patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior treatment.